Business Wire
09 Aug 2026, 21:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Silence Therapeutics will announce topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera on August 10, 2026. — Phase 2 topline data is a primary value driver for clinical-stage biotech companies and typically triggers significant price volatility.
+0.60Which stocks this story touches
The company is announcing a scheduled call to discuss trial results, which is a neutral administrative update.
Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
MarketBeat
3h ago
